Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE; male patient who was 15 years old when he received his first dose of GARDASIL 9 and he received a second dose of GARDASIL 9 yesterday on 10/14/2025 at the age of 25; This spontaneous report was received from a consumer regarding a 25-year-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 14-OCT-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 1 dosage form administered as prophylaxis (strength, exact dose, route of administration, anatomical site of injection, lot number, and expiration date were not reported). It was reported that the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) on an unknown date when he was 15 years old, and he received the second dose at 25 years old (Inappropriate schedule of product administration). No additional adverse events were reported. Lot number is being requested and will be submitted if received.